News and Trends 1 Dec 2016 UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […] December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 UPDATE: GSK is staging a comeback with a new Shingles Vaccine GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a Biologics License Application to the FDA for its shingles vaccine candidate, Shingrix. Though it is still experimental, the vaccine is proving itself superior to the […] November 30, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 Drugging the Undruggable: New Acquisition to Boost GPCR Drugs Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […] November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 New British Partnership set to Cure Rare Diseases with Gene Therapy Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet. Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 28 Nov 2016 Needle-Free Diabetes Monitoring: Interview with the Co-Founder of GlucoWise The needle-free revolution for diabetes is coming! We interviewed Panos Kosmas, co-founder of MediWise, to get the juicy details of GlucoWise. This revolutionary wireless device could free the more than 422 million people living with diabetes worldwide from the daily pain of conventional glucose monitoring. Panos Kosmas is the co-founder and Chief Technical Officer of MediWise, a […] November 28, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2016 Infographic: The Changing Face of UK Drug Discovery by the Numbers After Brexit, UK pharma is striving to reinvigorate drug discovery through collaboration. This infographic shows why that’s necessary. A new report from the Association of the British Pharmaceutical Industry (ABPI) has a grim finding: the UK is beginning to lose out on global drug discovery investment compared to 10 years ago. Spending on pharmaceutical R&D […] November 24, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 CRISPR meets RNAi: a whole new Targeted Therapy Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2016 USB key Diagnostic could help manage HIV Treatment Anywhere A new method of gene sequencing has brought us an HIV diagnostic on a “USB stick”, which determines the levels of the virus with one drop of blood and in under 30 minutes. Once perfected, the technology could be the tool for HIV management as glucose meters are for diabetes. While pharma and research work […] November 14, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 12 Nov 2016 The sound of this Spider Silk Violin surprises Expert Musicians Last week, Imperial College London hosted the International Student Innovation Awards. The winner astonished everyone with a violin made with spider silk. Luca Alessandrini was awarded the £10,000 prize for the design of a biomaterial-based violin that can be engineered to customize the final sound. With the new funds and a patent filed, the designer is now looking for co-founders to […] November 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […] November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 Evotec chooses Oxford as Proving Ground for Academia-Industry Bridge The German CRO has struck a deal with the University of Oxford to test a model framework for bringing academic research to the clinic faster. Evotec started out as a service provider in Hamburg, but thanks to former CEO Jörn Aldag, it has blossomed into a company that specializes in transforming newly discovered therapies into […] November 10, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 European Biotech is working hard to Beat back Melanoma Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […] November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email